Charles L Daley

Summary

Publications

  1. doi request reprint A summary of meeting proceedings on addressing variability around the cut point in serial interferon-γ release assay testing
    Charles L Daley
    Department of Medicine, National Jewish Health, Denver, Colorado 80206, USA
    Infect Control Hosp Epidemiol 34:625-30. 2013
  2. doi request reprint Management of multidrug resistant tuberculosis
    Charles L Daley
    Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO 80206, USA
    Semin Respir Crit Care Med 34:44-59. 2013
  3. pmc Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis
    Payam Nahid
    Curry International Tuberculosis Center, University of California, San Francisco, CA, USA
    BMC Infect Dis 11:1. 2011
  4. doi request reprint Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment
    Charles L Daley
    National Jewish Health, Division of Mycobacterial and Respiratory Infections, Denver, Colorado 80206, USA
    Curr Opin Organ Transplant 14:619-24. 2009
  5. pmc In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease
    Jakko van Ingen
    Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO, USA
    Antimicrob Agents Chemother 56:6324-7. 2012
  6. doi request reprint The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment
    Jakko van Ingen
    Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO, USA
    Am J Respir Crit Care Med 186:559-65. 2012
  7. doi request reprint Diagnosis and treatment of infections due to Mycobacterium avium complex
    Shannon H Kasperbauer
    Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado 80206, USA
    Semin Respir Crit Care Med 29:569-76. 2008
  8. pmc Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis
    Jerry A Nick
    Adult Cystic Fibrosis Program, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA
    Am J Respir Crit Care Med 182:614-26. 2010
  9. pmc Blood Transcriptional Biomarkers for Active Tuberculosis among Patients in the United States: a Case-Control Study with Systematic Cross-Classifier Evaluation
    Nicholas D Walter
    Pulmonary Section, Veterans Administration Medical Center, Denver, Colorado, USA Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, Aurora, Colorado, USA Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado, USA
    J Clin Microbiol 54:274-82. 2016
  10. ncbi request reprint Effect of drug resistance on the generation of secondary cases of tuberculosis
    Marcos Burgos
    Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University Medical Center, Stanford, California, USA
    J Infect Dis 188:1878-84. 2003

Collaborators

Detail Information

Publications17

  1. doi request reprint A summary of meeting proceedings on addressing variability around the cut point in serial interferon-γ release assay testing
    Charles L Daley
    Department of Medicine, National Jewish Health, Denver, Colorado 80206, USA
    Infect Control Hosp Epidemiol 34:625-30. 2013
    ..This report summarizes its proceedings...
  2. doi request reprint Management of multidrug resistant tuberculosis
    Charles L Daley
    Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO 80206, USA
    Semin Respir Crit Care Med 34:44-59. 2013
    ..This article reviews the management of MDR and XDR-TB and highlights the updated 2011 WHO guidelines on the programmatic management of drug-resistant tuberculosis...
  3. pmc Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis
    Payam Nahid
    Curry International Tuberculosis Center, University of California, San Francisco, CA, USA
    BMC Infect Dis 11:1. 2011
    ..Tuberculosis is a leading cause of death worldwide, yet the determinants of death are not well understood. We sought to determine risk factors for mortality during treatment of drug-susceptible pulmonary tuberculosis under program settings...
  4. doi request reprint Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment
    Charles L Daley
    National Jewish Health, Division of Mycobacterial and Respiratory Infections, Denver, Colorado 80206, USA
    Curr Opin Organ Transplant 14:619-24. 2009
    ..Infections due to nontuberculous mycobacterial (NTM) infections are increasing and, thus, it is likely that practitioners will see an increase in NTM infections in transplant recipients...
  5. pmc In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease
    Jakko van Ingen
    Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO, USA
    Antimicrob Agents Chemother 56:6324-7. 2012
    ..Synergy between clofazimine and other antibiotics with intracellular targets should be explored...
  6. doi request reprint The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment
    Jakko van Ingen
    Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO, USA
    Am J Respir Crit Care Med 186:559-65. 2012
    ..Currently recommended multidrug treatment regimens for Mycobacterium avium complex (MAC) lung disease yield limited cure rates. This results, in part, from incomplete understanding of the pharmacokinetics and pharmacodynamics of the drugs...
  7. doi request reprint Diagnosis and treatment of infections due to Mycobacterium avium complex
    Shannon H Kasperbauer
    Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado 80206, USA
    Semin Respir Crit Care Med 29:569-76. 2008
    ..Treatment consists of a macrolide, rifamycin, and ethambutol given three times weekly for noncavitary disease and daily with or without an aminoglycoside for cavitary disease...
  8. pmc Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis
    Jerry A Nick
    Adult Cystic Fibrosis Program, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA
    Am J Respir Crit Care Med 182:614-26. 2010
    ..Little is known concerning disease progression and outcomes in these cohorts...
  9. pmc Blood Transcriptional Biomarkers for Active Tuberculosis among Patients in the United States: a Case-Control Study with Systematic Cross-Classifier Evaluation
    Nicholas D Walter
    Pulmonary Section, Veterans Administration Medical Center, Denver, Colorado, USA Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, Aurora, Colorado, USA Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado, USA
    J Clin Microbiol 54:274-82. 2016
    ..Blood transcriptional signatures are promising for tuberculosis (TB) diagnosis but have not been evaluated among U.S...
  10. ncbi request reprint Effect of drug resistance on the generation of secondary cases of tuberculosis
    Marcos Burgos
    Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University Medical Center, Stanford, California, USA
    J Infect Dis 188:1878-84. 2003
    ..Here, we assess the relative pathogenicity of drug-resistant and drug-susceptible strains, in a human population...
  11. pmc Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands
    Sundari R Mase
    From the Division of Tuberculosis Elimination, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina North Bay Pediatrics, Vallejo, California Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado TB Leprosy Program, Federated States of Micronesia FSM Francis J Curry International TB Center, San Francisco, California and Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida
    Pediatr Infect Dis J 35:414-21. 2016
    ....
  12. doi request reprint Improvement in Quality of Life after Therapy for Mycobacterium abscessus Group Lung Infection. A Prospective Cohort Study
    Christopher A Czaja
    1 Department of Medicine, National Jewish Health, Denver, Colorado
    Ann Am Thorac Soc 13:40-8. 2016
    ..Mycobacterium abscessus group lung infection is characterized by low cure rates. Improvement in quality of life may be a reasonable treatment goal...
  13. doi request reprint Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease
    Jakko van Ingen
    Division of Mycobacterial and Respiratory Infections, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA
    Int J Antimicrob Agents 39:173-6. 2012
    ..simiae disease. A treatment regimen including a macrolide, moxifloxacin and one or two additional drugs based on DST results may be advisable; clofazimine and amikacin or streptomycin are potential candidates...
  14. ncbi request reprint Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis
    William J Burman
    Denver Public Health and the Department of Medicine, University of Colorado Health Sciences National Jewish Medical and Research Center, Denver, Colorado, USA
    Am J Respir Crit Care Med 174:331-8. 2006
    ..Moxifloxacin has promising preclinical activity against Mycobacterium tuberculosis, but has not been evaluated in multidrug treatment of tuberculosis in humans...
  15. ncbi request reprint Molecular epidemiology: a tool for understanding control of tuberculosis transmission
    Charles L Daley
    Division of Mycobacterial and Respiratory Infections, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
    Clin Chest Med 26:217-31, vi. 2005
    ..This article reviews some of the lessons learned using these new epidemiologic tools...
  16. pmc Genome sequencing of Mycobacterium abscessus isolates from patients in the united states and comparisons to globally diverse clinical strains
    Rebecca M Davidson
    Integrated Center for Genes, Environment, and Health, National Jewish Health, Denver, Colorado, USA
    J Clin Microbiol 52:3573-82. 2014
    ..Our study explores the genomic diversity of clinical M. abscessus strains from multiple continents and provides insight into the genome plasticity of an opportunistic pathogen. ..
  17. pmc Rapid diagnosis of pneumococcal pneumonia among HIV-infected adults with urine antigen detection
    David R Boulware
    Division of Infectious Disease and International Medicine, Department of Medicine, University of Minnesota, MMC 250, 420 Delaware St SE, Minneapolis, MN 55455, USA
    J Infect 55:300-9. 2007
    ..Streptococcus pneumoniae is the leading cause of bacterial pneumonia and associated bacteremia during HIV infection. Rapid diagnostic assays may limit inappropriate therapy...